Oramed Pharmaceuticals, Inc. (ORMP) has fallen 5.91% Monday In Premarket Trading

Oramed Pharmaceuticals, Inc. (ORMP) is lower by Monday morning, with the stock decreasing -5.91% in pre-market trading to 2.23. ORMP's short-term technical score of 39 indicates that the stock has traded less bullishly over the last month than 61% of stocks on the market. In the Biotechnology industry, which ranks 139 out of 146 industries, the stock ranks higher than 63% of stocks. Oramed Pharmaceuticals, Inc. has fallen 23.30% over the past month, closing at $3.04 on September 11. During this period of time, the stock fell as low as $2.31 and as high as $3.19. ORMP has an average analyst recommendation of Sell. The company has an average price target of $3.65.

ORMP has an Overall Score of 39. Find out what this means to you and get the rest of the rankings on ORMP!

See Full ORMP Report

Oramed Pharmaceuticals, Inc. has a Long-Term Technical rank of 22. This means that trading over the last 200 trading days has placed the company in the lower half of stocks with 78% of the market scoring higher. In the Biotechnology industry which is number 135 by this metric, ORMP ranks better than 135% of stocks.

Important Dates for Investors in ORMP:

-Oramed Pharmaceuticals, Inc. is set to release earnings on 2023-11-09. Over the last 12 months, the company has reported EPS of $0.28. -We do not have a set dividend date for Oramed Pharmaceuticals, Inc. at this time. Click Here To Get The Full Report on Oramed Pharmaceuticals, Inc. (ORMP)